Olga Shevetz
Rehovot, M, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Journal: JCI insight
Published: July 24, 2023
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Journal: JCI insight
Published: June 29, 2020
Peripheral Blood Cell Mitochondrial Dysfunction in Myelodysplastic Syndrome Can Be Improved by a Combination of Coenzyme Q10 and Carnitine.
Journal: Mediterranean journal of hematology and infectious diseases
Published: June 20, 2020
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Journal: Genes, chromosomes & cancer
Published: October 21, 2018
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Journal: British journal of haematology
Published: May 04, 2017
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Journal: Genes, chromosomes & cancer
Published: January 21, 2016
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Journal: British journal of haematology
Published: July 05, 2015
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Journal: European journal of haematology
Published: March 27, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026